RealTime Dynamix™: AS and Nr-AxSpA US 2018 Spotlight
Use of biologics in the management of axial spondyloarthropathies (AxSpA) has become well established. The spectrum of axSpA is becoming better understood and now includes inflammation in the absence of observable damage using radiographic techniques (nr-axSpA). A survey of 104 US rheumatologists in August revealed significantly fewer patients with nr-axSpA are treated with biologic/JAK agents compared to patients with AS, despite the majority of these patients being considered biologic-eligible. View complimentary highlights from the RealTime Dynamix™ report below.
Contact [email protected] for more information about the highlighted report or to see if your company already has access.
All company, brand or product names and logos in this document are trademarks of their respective holders.